Two types of magnetic brain stimulation for thinking problems in treatment-resistant schizophrenia
Compares two magnetic brain stimulation types with sham for cognition in schizophrenia.
Plain-language title generated from the registry record
Registry title: Comparison of Accelerated Intermittent Theta Burst Stimulation vs High Frequency Transcranial Magnetic Stimulation (Hf-rTMS) on Cognitivesymptoms in Treatment-resistant Schizophrenia
Key facts
- Where
- Bhubaneswar, IndiaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18-60 with treatment-resistant schizophrenia who have been taking clozapine for at least 6 months. It tests brain stimulation for thinking problems.
- Age
- 18-60 years
- Sex
- All sexes can join.
- Disease stage
- Treatment-resistant schizophrenia, diagnosed by TRIIP Consensus criteria.
- Earlier treatment
- Must have been taking clozapine for at least 6 months. Cannot have had ECT, rTMS or tDCS currently or recently.
Main reasons for not taking part
- Current or recent ECT, rTMS or tDCS
- Other psychiatric, major medical or neurological disorders
- History of withdrawal seizures, delirium tremens or significant head injury
- Pacemaker or metal in the body (except the mouth)
- Pregnant or breastfeeding women
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Source: NCT07445620, who can take part
Where in India
- AIIMS, BhubaneswarBhubaneswar, IndiaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- All India Institute of Medical Sciences, Bhubaneswar
- Trial code
- NCT07445620
- Record updated
- 10 August 2026
- Original description
This randomized, double-blind, sham-controlled trial compares three brain stimulation approaches-accelerated intermittent theta burst stimulation (aITBS), high-frequency repetitive transcranial magnetic stimulation (HF-rTMS), and sham stimulation-for treating cognitive deficits in treatment-resistant schizophrenia. Ninety patients receiving clozapine will be randomized 1:1:1 to receive 20 sessions over 4 weeks targeting the dorsolateral prefrontal cortex. The primary outcome is change in cognitive function measured by B-CATS score at 2, 4, and 12 weeks. Secondary outcomes include social cognition, symptom severity, brain metabolism (FDG-PET), and inflammatory biomarkers.Read full original descriptionShow less
Comparison of Accelerated Intermittent Theta Burst Stimulation vs High Frequency Transcranial Magnetic Stimulation (Hf-rTMS) on Cognitivesymptoms in Treatment-resistant Schizophrenia: DB-RCT
This randomized, double-blind, sham-controlled trial compares three brain stimulation approaches-accelerated intermittent theta burst stimulation (aITBS), high-frequency repetitive transcranial magnetic stimulation (HF-rTMS), and sham stimulation-for treating cognitive deficits in treatment-resistant schizophrenia. Ninety patients receiving clozapine will be randomized 1:1:1 to receive 20 sessions over 4 weeks targeting the dorsolateral prefrontal cortex. The primary outcome is change in cognitive function measured by B-CATS score at 2, 4, and 12 weeks. Secondary outcomes include social cognition, symptom severity, brain metabolism (FDG-PET), and inflammatory biomarkers.
Inclusion: Diagnosed with treatment-resistant schizophrenia according to TRIIP Consensus criteria; Age: 18-60 years; Currently receiving clozapine treatment for at least 6 months; Attending psychiatry outpatient department at AIIMS Bhubaneswar.
Exclusion: Currently receiving or recently received ECT/rTMS/tDCS; Co-morbid psychiatric, major medical, or neurological disorders; History of withdrawal seizures, delirium tremens, or significant head injury; Presence of pacemaker or metal in any part of body (excluding mouth); Pregnant or lactating women.